Noscendo is pursuing clinical actionability and cost evidence for its cfDNA metagenomic sequencing platform in sepsis through a new €7.5 million German project. The effort, called OptiSep, will test the Disqver platform as part of a 3.5-year study funded by Germany’s G-BA innovation committee. The program builds on results from the earlier DigiSep interventional trial, which analyzed cfDNA sequencing alongside standard-of-care blood culture in 410 patients across 24 hospitals. OptiSep will expand the focus to interoperable routine data and use multiple German clinical sections and DIVI management through Leipzig University Hospital. For diagnostics companies and hospital systems, the key operational milestone is whether cfDNA sequencing can drive clinically actionable decisions and demonstrate value in routine settings where blood culture turnaround and interpretability remain limiting factors.